MM425B

antibody from Invitrogen Antibodies

Targeting: IL1B IL-1B, IL1-BETA, IL1F2

Western blot

ELISA

Antibody data

Submit

Validation data

Product number: MM425B - Provider product page
Provider: Invitrogen Antibodies
Product name: IL-1 beta Monoclonal Antibody (1400.24.17)
Antibody type: Monoclonal
Antigen: Recombinant full-length protein
Description: MM425B targets IL-1 beta in WB and ELISA applications and shows reactivity with mouse samples. The MM425B immunogen is recombinant mouse IL-1 beta. MM425B detects IL-1 beta which has a predicted molecular weight of approximately 17 kDa. This product has been tested for endotoxins by limulus amoebocyte lysate (LAL) assay and contains an endotoxin concentration of less than or equal to 10 endotoxin units per milligram (EU/mg).
Reactivity: Human, Mouse
Host: Mouse
Isotype: IgG
Antibody clone number: 1400.24.17
Vial size: 500 μg
Concentration: 1.0 mg/mL
Storage: -20°C

IL1B protein structure - MM425B shown in red.

Supportive validation

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Effects of 4-PBA on the levels of IFN-gamma, TNF-alpha, IL-1beta, ICAM-1, KC, and VEGF protein in lung of LPS-treated mice. Sampling was performed at 48 hours after LPS treatment in 0.9% NaCl solution (saline)-treated mice administered with drug vehicle (PBS) (SAL+PBS), LPS-treated mice administered with PBS (LPS+PBS), or LPS-treated mice administered with 4-PBA (LPS+PBA). Representative Western blots of IFN-gamma (a), TNF-alpha (c), IL-1beta (e), and ICAM-1 (g) in the lung tissues and of KC (i) and VEGF (k) in the BAL fluids. Analyses of band intensity on films are presented as the relative ratio of IFN-gamma (b), TNF-alpha (d), IL-1beta (f), and ICAM-1 (h) to actin, while in case of KC and VEGF, analyses of band intensity on films are presented as the relative ratio of the level of KC (j) and VEGF (l) in each group to the level in SAL+PBS. The relative ratio of each protein in the lung tissues of SAL+PBS is arbitrarily presented as 1. Bars represent mean +- SEM from 8 mice per group. # P < 0.05 versus SAL+PBS; * P < 0.05 versus LPS+PBS.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 1 FIGURE Pyroptosis levels were decreased in non-small cell lung cancer (NSCLC) tissues and cell lines. (a and c) The mRNA levels of pyroptotic-related genes (NLRP3, caspase-1, IL-1beta, and IL-18) in NSCLC tissues, adjacent noncancerous tissues, NSCLC cell lines (A549, H358, and H520), and normal lung epithelial cell line BEAS-2B were analyzed by using qRT-PCR. (b and d) The proteins levels of pyroptotic-related genes (NLRP3, caspase-1, IL-1beta, and IL-18) in NSCLC tissues, adjacent noncancerous tissues, NSCLC cell lines (A549, H358, and H520), and normal lung epithelial cell line BEAS-2B were analyzed by using western blot. GAPDH is chosen as protein controls. ** p < .01

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 6 FIGURE Huaier suppresses tumor growth and induces pyroptosis in vivo. Tumorigenesis assay was performed by subcutaneous injection of H520 cells into flanks of BALB/c nude mice. (a) Tumor volumes were measured at the indicated days post-injection. (b) The effect of huaier on apoptosis in tumor tissues was evaluated by TUNEL assay. (c) The western blot analysis detected the relative expression of Ki-67, NLRP3, caspase-1, IL-1beta, and IL-18 in tumor tissues. (d) Bodyweight of mice in the vehicle group, low dose group (50 mg/ml), and high dose group (100 mg/ml) were evaluated every 3 days. (e) H&E staining was applied to evaluate the changes in the heart, liver, spleen, lung, and kidney tissues. ** p < .01

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 9 Upregulated IL-1beta inhibits muscle differentiation in A/J myoblasts. a Quantitation of myotube fusion in WT or A/J myoblasts treated with indicated concentrations of IL-1beta for 72 h. Percent myotube fusion was calculated from MyHC-positive immunostaining. b Quantitation of MyoD-positive cells are shown as percent of total nuclei in WT or A/J myoblast cultures treated with indicated concentrations of IL-1beta for 72 h. c Immunofluorescence staining of myoblast cultures after treatment with an IL-1beta blocking antibody (IL-1beta mAb). WT and A/J cultures were plated at equal density and treated with 4 ng/ml of IL-1beta mAb for 72 h. Control cultures were treated with equimolar concentrations of mouse IgG. Fixed cultures were stained with anti-MyoD (green) and anti-MyHC (red) antibodies. d Quantitation of myotube fusion in treated cultures. e Quantitation of MyoD-positive cells in treated cultures. f - h Gene expression of MyoD ( f ), Myf5 ( g ), and myogenin ( h ) determined by qRT-PCR in cultures treated with indicated concentrations of IL-1beta mAb. n = 3. Data are shown as means +- SEM. * P < 0.05; ** P < 0.01; *** P < 0.005

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 7 Role of chemerin in the activation of pyroptosis in vitro. a Protein levels of NLRP3, active caspase-3, active caspase-7, and active caspase-8 were detected by western blotting in macrophages treated with chemerin. Macrophages were isolated from the peritoneal cavity of normal mice and stimulated with 10 nM chemerin for 3 and 12 h, respectively. b Measurement of lactate dehydrogenase (LDH) activity in macrophages treated with chemerin for 3 and 12 h. c Protein expression of pro-caspase-1, pro-IL-1beta, and pro-IL-18 in macrophages (left) and the levels of caspase-1, IL-1beta, and IL-18 in the culture supernatants of macrophages (right) under the chemerin treatment condition. *Chemerin group vs. controls. #Chemerin group with ChemR23 knockdown vs. chemerin group, under the chemerin treatment for 3 h. @Chemerin group with ChemR23 knockdown vs. chemerin group, under chemerin treatment for 12 h. **, ##, and @@-- P < 0.01